Brief: Lytix Biopharma's Partner Verrica Announces Pricing Of Underwritten Public Offering
Nov 22 (Reuters) - Lytix Biopharma AS LYTIX.OL :
* SAID ON THURSDAY LICENSING PARTNER VERRICA PHARMACEUTICALS
ANNOUNCES THE PRICING OF A UNDERWRITTEN PUBLIC OFFERING, RAISING
APPROXIMATELY USD 42 MILLION UPON COMPLETION
Source text: ID:nObiDj3hqa
Further company coverage: LYTIX.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Lytix Biopharma AS
See all newsBrief: Lytix Biopharma Q3 Loss Widens To NOK 23.3 Mln
Brief: Lytix Biopharma Announces Interim Data On Neoadjuvant Treatment Of Melanoma
Brief: Lytix Biopharma Q1 Operating Loss Narrows To NOK 13.4 Mln
Brief: Lytix Biopharma Q4 Total Operating Income Nok 377,000
Brief: Lytix Biopharma Gets Notice Of Allowance For US Patent Application For Ltx-315 Clinical Program